ImmunoGen, Inc. Announces Webcast of Presentation at the 27th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 8, 2009--ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference at 9:30 am PST on January 15, 2009. The Conference is being held at the Westin St. Francis hotel in San Francisco, CA. ImmunoGen's presentation will be webcast live and can be accessed through the "Investor Information" section of our website, www.immunogen.com. An archive of the webcast will be available at the same location until January 22, 2009.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and the naked antibody AVE1642 is in clinical trials through the Company's collaboration with sanofi-aventis. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.
CONTACT:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
